We will emphasize the necessity of early positioning in the drug development process and its cross-functional nature.
Discuss the common mistake of late positioning and the benefits of integrating positioning strategies before designing phase three trials.
Hear real-world examples to illustrate the impact of early positioning on product success.
Understand how early positioning is a critical precursor to a successful product launch, avoiding rigid phase three protocols that limit strategic flexibility.
Guru Muralimohan, PhD, Executive Director, Early Pipeline Commercialization, Oncology, Bayer US
Monday September 30, 2024 9:45am - 10:30am EDT
Log in to save this to your schedule, view media, leave feedback and see who's attending!
